To The Moon

Hims & Hers:  The High Stakes Gamble for a Weight Loss Revolution 

🌟🌟🌟The energy around $Hims & Hers Health Inc.(HIMS)$  right now is electric - a mix of raw excitement and hold your breath anxiety.  After watching $Eli Lilly(LLY)$  deliver a powerhouse earnings that sent its stock surging 10%, we are all asking the same question : Can HIMS do it too?

It feels like we are standing on the edge of a fundamental shift.  While Lilly owns the crown of the innovator, Hims & Hers is playing a more emotive game - the game of access.  HIMS is betting that the miracle of weight loss should not be just for those who can afford the branded premium, but for everyone.  On Monday, May 11, we find out if that bet is finally paying off in the numbers.

What the Analysts Are Saying 

Wall Street is currently a house divided.  Some see a disruptor about to explode.  Others see a legal minefield.

The Consensus : The average 12 month price target is USD 31.86, implying a modest 12% upside from current levels.

The Highs and Lows: The range is staggering, from a "to the moon" high of USD 68 to a "back to earth" low of USD 18.00.

Recent Upgrades: Major players like JPMorgan recently initiated coverage with an Overweight rating and a USD 35 target.  Bank of America boosted its target to USD 32 following the company's deepening ties with the broader medical ecosystem.

Can HIMS Follow Lilly?

If we look at the risk to reward psychology, HIMS is currently one of the most polarising stocks on the market.

Here is how the situation currently is:

The Lilly tailwinds are real:

When Eli Lilly crushes earnings, it confirms that the total addressable market or TAM for weight loss isn't just big, it is generational.  People aren't just buying these drugs, they are fighting for access to them.  This insatiable demand is the best possible backdrop for HIMS.  If the market leader can't keep up with the supply, the disruptor HIMS naturally wins the spillover.

The Great Compounding Gamble:

The reason HIMS has not already followed LLY to the moon is the regulatory overhang.  The FDA allows compounding mainly during shortages.  If the big pharma companies fix their supply chains, the legal window for HIMS could narrow.

The Bull Case :  HIMS is building a brand, not just a pharmacy.  They are betting that once a customer is in their ecosystem for a lifestyle drug, they won't leave just because the branded version becomes available.

The Bear Case : You are essentially betting against the legal departments of $Novo-Nordisk A/S(NVO)$  and Eli Lilly.  That is a heavy bet and a big risk.

HIMS Earnings Trap vs The Squeeze 

With around 35% short interest, HIMS is a tinderbox.

If they report a slight miss or give cautious guidance on the FDA/legal front , the shorts will pounce and it could be a bloodbath.

However if HIMS shows massive subscriber growth in the weight loss category, proving that the Lilly spillover is real, the short squeeze could be violent and legendary.

Concluding Thoughts 

I believe that HIMS is a conviction play.  It is not for the risk adverse investor.  HIMS is a stock for those who believe that the democratisation of healthcare will eventually prevail.  This means cheaper and easier access via tech for everyone.

HIMS is a high octane, high risk kind of stock that has the DNA of a multi bagger.  But like any high growth disruptor, it is currently a battleground between a massive potential and regulatory reality.

The Verdict: If you believe HIMS can successfully transition users from compounded semaglutide to a broader, lifelong holistic health subscription, it has all the makings of a 10x player over the next decade.  But it is a high volatility bet - the kind that either makes you a fortune or leaves you holding the bag.

@Tiger_comments  @TigerStars  @Tiger_SG  @TigerClub  @CaptainTiger